Trial Profile
Adjuvant Nivolumab in Resected Lung Cancers (ANVIL)-A Randomized Phase III Study of Nivolumab After Surgical Resection and Adjuvant Chemotherapy in Non-Small Cell Lung Cancers
Status:
Active, no longer recruiting
Phase of Trial:
Phase III
Latest Information Update: 08 Mar 2024
Price :
$35
*
At a glance
- Drugs Nivolumab (Primary)
- Indications Non-small cell lung cancer
- Focus Therapeutic Use
- Acronyms ALCHEMIST-Immunotherapy; ALCHEMIST-nivo; ANVIL
- 18 Mar 2023 Planned End Date changed from 1 Sep 2025 to 31 Dec 2025.
- 18 Mar 2023 Planned primary completion date changed from 1 Sep 2025 to 31 Dec 2025.
- 09 Aug 2022 Planned primary completion date changed from 1 Jul 2024 to 1 Sep 2025.